Nanolattix’s T320-ADC Multi-Center Clinical Trials Initiated, Accelerating Development of Advanced Solid Tumor Therapies
Release time:
2025-07-09
Nanolattix’s independently developed T320-ADC (antibody-drug conjugate) project—“An Open-Label, Multi-Center Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of T320 (ADC) in Patients with Advanced Solid Tumors”—has recently been initiated at multiple centers, including Shanxi Provincial Cancer Hospital, The First Affiliated Hospital of Xi’an Jiaotong University, and Hunan Cancer Hospital. This marks substantial progress in the clinical development of this innovative, proprietary drug.
T320 is a key oncology candidate in Nanolattix’s pipeline, drawing significant industry attention due to its unique mechanism of action, notable anti-tumor efficacy, and favorable safety profile demonstrated in preclinical studies. Designed to target multiple advanced solid tumors—including cervical, ovarian, and pancreatic cancers—the drug’s standout advantage lies in its potential to overcome resistance to existing therapies, offering a promising new treatment option for patients.
The simultaneous advancement of T320’s clinical trials across multiple centers will not only facilitate efficient, multi-dimensional data collection but also expand patient access, reflecting Nanolattix’s strong clinical execution capabilities and commitment to delivering innovative treatments to those in need. The company will adhere to a rigorous, science-driven R&D approach, strictly complying with Good Clinical Practice (GCP) guidelines, to accelerate T320’s clinical development and future commercialization, ultimately striving to provide superior therapeutic solutions for global cancer patients.
Tag:
Next Page
Next page:
recommend News
Share
